In recent years, advances in the humanized mouse system have led to significantly increased levels of human hematopoietic stem cell (HSC) engraftment. The remaining limitations in human HSC engraftment and function include lymphoid-skewed differentiation and inefficient myeloid development in the recipients. Limited human HSC function may partially be attributed to the inability of the host mouse microenvironment to provide sufficient support to human hematopoiesis. To address this problem, we created membrane-bound human stem cell 
Introduction
The humanized mouse system, a xenogeneic transplantation and engraftment model for human hematopoietic stem cells (HSCs) and peripheral blood mononuclear cells (MNCs), facilitates the investigation of human hematopoietic and immune systems in vivo 1, 2 . Since the pioneering work using SCID-hu 3 and Hu-PBL-SCID models 4 , investigators have attempted to better recapitulate human biology in mice across xenogeneic immunological barriers. Recently, the introduction of targeted null mutations of immune-related genes such as Rag1, Rag2, Il2rg, or Prf1 in recipient mice has improved engraftment levels of human CD45+ leukocytes 2, [5] [6] [7] [8] [9] . However, limitations remain in the ability of the host mouse hematopoietic In order to create a hematopoietic microenvironment more suitable for human myeloid development, we developed a new immune-compromised mouse strain that expresses human membrane bound stem cell factor (SCF) under the control of the phosphoglycerate kinase (PGK) promoter (hSCF Tg NSG). By using hSCF Tg NSG mice as recipients of human HSCs, we aimed to clarify the role of membrane-bound form of SCF in supporting the engraftment of human hematopoietic cells and influencing the differentiation of the human myeloid lineage in the recipient mouse bone marrow (BM), spleen and other organs. Here we show nearly complete human hematopoietic chimerism in the BM of hSCF Tg NSG recipients.
In the BM of these recipients, human granulocytes accounted for the majority of engrafted human cells reflecting the physiological human BM status. In addition to the development of immature and mature granulocytes, c-Kit+ human mast cells differentiated efficiently in BM, spleen, and mucosal tissues. The hSCF Tg NSG mice, by supporting efficient human myeloid development including mast cells, may serve as a novel platform for in vivo investigation of human mast cell development and allergic responses.
Methods
For personal use only. Tg(PGK1-KITLG*220)441Daw/J, abbreviated as hSCF Tg NSG mice, were generated at The Jackson Laboratory. The human membrane-bound SCF transgene driven by the human PGK promoter was backcrossed more than 10 generations from the original C3H/HeJ strain background 13 onto the NSG strain. All the mice were bred and maintained at The Jackson Laboratory and animal facility at RIKEN RCAI under defined flora according to guidelines established and approved by the Institutional Animal Committees at each respective institution.
Purification and transplantation of human HSCs
All experiments were performed with authorization from the Institutional Review Board for Human Research at RIKEN RCAI. Cord blood (CB) samples were first processed for isolation of MNCs using LSM lymphocyte separation medium (MP Biomedicals). CB MNCs were then enriched for human CD34+ cells by using anti-human CD34 microbeads (Miltenyi Biotec) and sorted for 7AAD(-)lineage (hCD3/hCD4/hCD8/hCD19/hCD56)(-)CD34+CD38(-) HSCs using FACSAria (BD Biosciences). To achieve high purity of donor HSCs, doublets were excluded by analysis of FSC-height/FSC-width and SSC-height/SSC-width. Purity of each sorted sample was higher than 95%. Newborn (within two days of birth) hSCF Tg and non-Tg NSG recipients received 150 cGy total body irradiation using a 137 Cs-source irradiator, followed by intravenous injection of 5×10 2 -5.3x10 4 sorted HSCs via the facial vein.
Analysis of human cell engraftment by flow cytometry
The recipient peripheral blood (PB) harvested from the retro-orbital plexus was evaluated for human hematopoietic engraftment every three to four weeks starting at 4-6 weeks post-transplantation. After lysis of erythrocytes, cells were stained with anti-hCD45, anti-msCD45, anti-hCD3, anti-hCD19, anti-hCD33, and anti-hCD56 to determine human hematopoietic chimerism and to analyze cell lineages engrafted in the recipients. At 8-35
weeks post-transplantation, the recipients were euthanized and single cell suspensions of BM and spleen were analyzed using flow cytometry. Antibodies used for flow cytometry are specified in Supplemental Methods. The labeled cells were analyzed using FACSCantoII or FACSAria (BD Biosciences).
Morphological analysis of cytospin specimens
Cytospin specimens of FACS-purified human myeloid cells were prepared with a Shandon Cytospin 4 cytocentrifuge (Thermo Electric) using standard procedures. To identify nuclear
For personal use only. on April 20, 2017. by guest www.bloodjournal.org From and cytoplasmic characteristics of each myeloid cell, cytospin specimens were stained with 100% May-Grünwald solution (Merck) for 3 minutes, followed by 50% May-Grünwald solution in phosphate buffer (Merck) for additional 5 minutes, and then with 5% Giemsa solution (Merck) in phosphate buffer for 15 minutes. All staining procedures were performed at room temperature. Light microscopy was performed with Zeiss Axiovert 200 (Carl Zeiss).
Microarray analysis
Purified hCD45+CD33+c-Kit(-)CD203c(-)HLA-DR(-) granulocytes and hCD45+CD33+ c-Kit(-)CD203c(-)HLA-DR+CD14+ monocytes from BM of four hSCF Tg NSG recipients and three non-Tg NSG recipients as well as neutrophils and monocytes from two healthy individuals were evaluated using Human Genome U133 plus 2.0 GeneChips (Affymetrix).
Total RNA was extracted with TRIzol (Invitrogen) from > 10 4 sorted cells, and amplified to cDNA using the Ovation Pico WTA System (Nugen 
Immunohistochemistry (IHC) and immunofluorescence imaging
Thin (~5um) sections prepared from paraformaldehyde-fixed paraffin-embedded tissues were stained with H&E using standard procedures. IHC and immunofluorescence labeling were performed using standard procedures. Antibodies used for IHC and immunofluorescence
For personal use only. on April 20, 2017. by guest www.bloodjournal.org From 6 labeling were mouse anti-human mast cell tryptase monocolonal antibody (Dako, clone AA1), mouse anti-human CD45 monoclonal antibody (Dako, clone 2B11+PD7/26), rabbit anti-human CD117 monoclonal antibody (Epitomics, clone YR145) and rabbit anti-human CD14 polyclonal antibody (Atlas Antibodies). Light microscopy was performed using an Axiovert 200 (Carl Zeiss). For quantification of tryptase+ cell frequency, three high-power fields from three different recipients were examined using AutoMeasure module of AxioVision software (Release 4, Carl Zeiss). Confocal microscopy was performed using a LSM710 (Carl Zeiss).
For personal use only. on April 20, 2017. by guest www.bloodjournal.org From
Results

Human hematopoietic repopulation is enhanced in hSCF Tg NSG recipients
The humanized mouse model system has served as a tool to investigate human hematopoiesis, immunity and diseases in vivo. However, one of the major limitations in the system is that the microenvironment supporting human hematopoiesis and immunity is primarily of mouse origin. In the present study, we created a strain of NSG mice expressing membrane-bound human SCF to analyze the role of the BM microenvironment in human hematopoietic lineage determination and development.
c-Kit, the receptor for SCF, is expressed at lower levels in human CB Lin(-)CD34+CD38(-) early HSCs and at high levels in mast cells [17] [18] [19] . Figure 1A ). Anemia in hSCF Tg NSG recipients was not associated with abnormalities in MCV, MCH or MCHC ( Figure S1 ). The suppression of host erythropoiesis in the hSCF Tg NSG recipients was related to the irradiation and engraftment of the human HSCs, since unmanipulated non-transplanted hSCF Tg NSG mice did not develop anemia ( Figure S1 ). Impaired mouse erythropoiesis in these engrafted hSCF Tg NSG mice was associated with rapid expansion of hCD45+ hematopoietic cells compared with non-Tg NSG recipients ( Figure 1B n=10 and non-Tg NSG controls: 11.4 +/-3.6%; n=10) (p=0.0601) ( Figure S2 ). We next analyzed the development of human lymphoid and myeloid cells in the engrafted human CD45+ hematopoietic cell populations by flow cytometry using monoclonal antibodies against hCD3, hCD19, hCD56, and hCD33 along with anti-human and anti-mouse CD45 antibodies ( Figure 1C , E). While there was recipient-to-recipient variability, the frequency of human CD33+ myeloid cells within the total human CD45+ population was significantly higher in the hSCF Tg NSG recipient BM than in the non-Tg NSG recipient BM and constituted the majority of human hematopoietic cells (hSCF Tg: 49.7 +/-4.0%; n=21 and non-Tg NSG controls: 26.2 +/-2.9%; n=13) (p=0.0002 by two-tailed t test). In contrast, in non-Tg NSG recipients, the majority of human hematopoietic cells in the BM were B cells (53.3 +/-4.5%; n=13), consistent with previous reports 5, 9, 20 . These findings demonstrate that the expression of membrane-bound hSCF in BM microenvironment results in significantly more efficient engraftment of human HSCs as well as enhanced development of human CD33+ myeloid cells from the engrafted human HSCs.
Human myeloid lineage development in hSCF Tg NSG recipients
Next, we examined the development of human myeloid subsets in the human membrane-bound SCF-expressing BM microenvironment. Flow cytometry scatter plots demonstrate the development of the side-scatter high granulocyte fraction in hSCF Tg NSG recipients which correlate with CD33+HLA-DR(-) cells (Figure 2A, B) . To quantify the frequencies of different myeloid subsets in these recipients, we first identified CD33+c-Kit(+)CD203c+ mature human mast cells among human CD45+ cells. Next, we identified CD33+HLA-DR(-) human granulocyte lineage cells and human CD33+HLA-DR(+) antigen presenting cells (APCs) among human CD45+ cells excluding mature mast cells ( Figure 2C ).
In the hSCF Tg NSG recipient BM, there were increased percentages of CD33+HLA-DR(-) granulocytes and decreased percentages of CD33+HLA-DR(+) APCs compared with non-Tg NSG controls (hSCF Tg: 46.7 +/-5.9% and 38.3 +/-4.0%, respectively; n=20 and non-Tg NSG controls: 25.8 +/-5.0% and 65.5 +/-4.1%, respectively; n=12) (p=0.0204 and p=0.0001 by two-tailed t test, respectively) ( Figure 2D ). In the BM of 11 out of 20 hSCF Tg NSG recipients examined, c-Kit(-)CD203c(-)HLA-DR(-)side scatter (high) granulocytes accounted for the highest frequency of total human myeloid cells ( Figure 2D , For personal use only. on April 20, 2017. by guest www.bloodjournal.org From Table 1 ). To examine the morphological features of the human granulocytes developing in the hSCF Tg recipients, we carried out May-Grunwald Giemsa (MGG) staining using cytospin specimens of FACS-purified CD33+c-Kit(-)CD203c(-)HLA-DR(-) cells from BM of hSCF Tg and non-Tg NSG recipients. In nine out of 13 hSCF Tg recipient BM cells examined, the majority of myeloid cells showed the morphology of immature granulocytes with large nuclear-to-cytoplasmic ratio and nuclei with few lobulations, largely consisting of myelocytes and metamyelocytes (S4-1 and S12-2 shown as representative in Figure 2E ). In four out of 13 hSCF Tg recipients examined and in four out of five non-Tg NSG recipients, mature segmented neutrophils were present in the sorted CD33+c-Kit(-)CD203c(-)HLA-DR(-) granulocyte population (N12-1 and S2-1 shown as representative in Figure 2E ). These Figure 2F ). We next examined whether there were any differences in gene expression within three distinct granulocyte sources (hSCF Tg recipient BM, non-Tg NSG recipient BM and primary human BM neutrophils) ( Figure 2G ). As seen in the heat-map representation, we found clusters of genes differentially transcribed in the distinct sources of granulocytes ( Figure 2G ). Multiple genes associated with transcriptional regulation were included in the genes up-regulated in human immature granulocytes derived from the BM of hSCF Tg NSG mice, suggesting that these cells are more actively cycling and proliferating compared with mature granulocytes from the BM of hSCF Tg NSG and non-Tg NSG mice and primary human BM neutrophils ( Figure 2G , Table S1 and S2).
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Development of human mast cells in hSCF Tg NSG recipients
We next investigated the development of human mast cells in the membrane-bound hSCF expressing NSG mice. Overall, the frequencies of cKit(+)CD203c+ cells within total BM CD33+ myeloid cells were similar between hSCF Tg NSG and non-Tg NSG recipients when excluding two non-Tg NSG recipients observed for more than 8 months (p=0.1439 by two-tailed t test) ( Figure 2D , Table 1 ). In seven of 20 hSCF Tg NSG recipients, compared with one of ten non-Tg NSG recipients, the frequency of cKit(+)CD203c+ cells in BM CD33+ cells was greater than 15% ( Figure 2D , Table 1 ). When these cKit(+)CD203c+ cells were FACS-purified and examined by MGG staining, their morphology was consistent with mast cells with varying degrees of cytoplasmic granulation ( Figure 3A ,B). Histological examination of HE-stained bone sections showed increased cellularity in hSCF Tg NSG recipients compared with non-Tg NSG recipients ( Figure 3C ). We then performed IHC staining for mast cell tryptase to identify human mast cells in the BM. Consistent with the quantitative analysis by flow cytometry, tryptase+ cells were abundantly observed in the hSCF Tg NSG recipients compared with non-Tg NSG recipients ( Figure 3C ). This does not reflect an increase in mouse mast cells since nearly all nucleated hematopoietic cells in the hSCF Tg NSG recipients are of human origin ( Figure 1D ). The same sections were further subjected to the immunofluorescence staining followed by confocal imaging demonstrating that these are mast cells and not CD14+ monocytes ( Figure S4 ). To date, several mouse strains have been developed for supporting normal and malignant human hematopoietic cell engraftment and normal myeloid cell differentiation by using Il2rg null immune-compromised mice (Table S3) . 5, 6, 8, 9, 20, [38] [39] [40] [41] Among these, human thrombopoietin (TPO) knock-in Rag2 null Il2rg null mice were reported to support both human hematopoietic engraftment and myeloid differentiation in the bone marrow. Both SCF and TPO exhibit species-specificity between man and mouse in supporting HSCs and myeloid cells in both species. These approaches focusing on the two distinct molecules based on the two immune-compromised mouse backgrounds will allow us to investigate human hematopoiesis and immunity from stem cells to myeloid progenitors to mature myeloid effecter cells in vivo. Tg NSG recipient spleen (S1-2: 85.7%, S1-3: 77.7%, and S12-3: 56.1% human mast cells weeks; S1-2: sacrificed at 20 weeks; S1-3: sacrificed at 21 weeks; S12-3: sacrificed at 13 weeks) (D) H&E-and anti-mast cell tryptase antibody-stained spleen sections demonstrating the presence of human mast cells in non-Tg NSG recipients and hSCF Tg NSG recipients.
Non-Tg NSG recipient -N11-1: 94.0% hCD45+. hSCF Tg NSG recipients -S11-1: 95.3%
and S9-1: 97.0% hCD45+. (N11-1: sacrificed at 20 weeks; S11-1: sacrificed at 10 weeks; S9-1: sacrificed at 16 weeks) Figure 5 Human mast cell development in hSCF Tg NSG recipient stomach, small and large intestine.
H&E-and anti-mast cell tryptase antibody-stained sections of (A) non-Tg NSG recipient stomach (NSG control: N1-3), small intestine (N5-1) and large intestine (N9-1) and (B) hSCF Tg NSG recipient stomach (S1-3), small intestine (S12-3) and large intestine (S12-3)
demonstrating the presence of human mast cells. (N1-3: sacrificed at 24 weeks; N5-1:
sacrificed at 35 weeks; N9-1: sacrificed at 20 weeks; S1-3: sacrificed at 21 weeks; S12-3:
sacrificed at 13 weeks) (C) Confocal immunofluorescence images of hSCF Tg stomach (S1-9) demonstrate human CD45+ (green) and human CD117+ (red) 
